摘要
目的:对莫西沙星与左氧氟沙星治疗尿路感染的临床效果进行评价,为临床应用提供循证医学证据。方法:以"莫西沙星"、"左氧氟沙星"、"尿路感染"等为主题词或关键词全面查询国内发表文献的数据库,运用Rev Man 5.1软件对符合条件的结果进行分析。结果:共纳入12篇文献,总样本量1110例,Meta分析结果为有效性、治愈率、不良反应发生率及细菌清除率的合并OR值分别为1.81(P=0.01)、1.67(P=0.002)、0.75(P=0.21)、1.70(P=0.10)。结果提示莫西沙星的疗效优于左氧氟沙星,不良反应发生率及细菌清除率与左氧氟沙星相比差异无统计学意义。针对莫西沙星口服及静脉两种给药方法进行亚组分析,结果提示口服给予莫西沙星治疗尿路感染的有效率及治愈率高于左氧氟沙星,而静脉给予莫西沙星有效率及治愈率与左氧氟沙星相比差异无统计学意义。结论:在尿路感染治疗中,莫西沙星较左氧氟沙星疗效好,安全性好,但由于样本量小、研究质量不高、方法描述不详等,只能为临床研究提供低强度证据。
Objective： To evaluate the efficacy and safety of moxifloxacin as well as levofloxacin in the treatment ofurinary tract infections, and provide evidence for clinical therapy in China. Methods： We searched the data base in China to collectall the original studies with the key words as moxifloxacin, levofloxacin, urinary tract infection. Data were analyzed by Rev Man 5.1software. Results： A total of 12 randomized controlled trials involving 1110 patients were included. The values of combined OR forefficacy, clinical cure rate, incidence of adverse reaction and bacterial eradication rate were 1.81 （P = 0.01）, 1.67 （P = 0.002）, 0.75 （P = 0.21）,1.70 （P = 0.10） respectively. Meta-analysis showed that moxifloxacin was more effective than levofloxacin in the treatment of urinarytract infections. However, there was no statistical difference in incidence of adverse reaction and bacterial eradication rate. Subgroupanalysis of oral and intravenous administration indicated that oral moxifloxacin was better than levofloxacin in efficacy and clinicalcure rate in the treatment of urinary tract infections, while intravenous moxifloxacin showed no statistical difference compared withlevofloxacin. Conclusion： Moxifloxacin was an effective and safe antibacterial agent in the treatment of urinary tract infections, andthe result should be authenticated in the future with many samples, high quality study, detail method description, etc.
出处
《中国药物应用与监测》
CAS
2014年第2期71-76,共6页
Chinese Journal of Drug Application and Monitoring
基金
国家科技部十二五重大专项滚动课题(2012ZX09303004-002)
